Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG +6.43%61 Cash Ratio is 4.75 as of Mar. 2026, which is 23% above its 10-year median of 3.85. GuruFocus rates TXG with a GF Score™ of 61/100 and a GF Value™ of $18.78 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 665 Healthcare Providers & Services companies, 10x Genomics ranks better than 91.58% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
10x Genomics Cash Ratio Related Terms
10x Genomics Cash Ratio Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Cash Ratio of 4.75 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on 10x Genomics and its competitors. This is 23% above median its historical median of 3.85. Over the past decade, 10x Genomics' Cash Ratio has ranged from 1.30 to 8.86. According to the industry distribution chart, 10x Genomics ranks #56 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 8.4%.
Is 10x Genomics' Cash Ratio too high?
10x Genomics' current Cash Ratio of 4.75 is 23% above median its 10-year median of 3.85. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 8.86. The Healthcare Providers & Services industry median Cash Ratio is 0.58. 10x Genomics' value of 4.75 is 719% above this industry median. Based on the distribution chart, 10x Genomics ranks #56 out of 665 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Cash Ratio compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #56 out of 665 companies for Cash Ratio. This places 10x Genomics in the top 8% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.58. 10x Genomics' value of 4.75 is 719% above this benchmark. Historically, 10x Genomics' own Cash Ratio has ranged from 1.30 to 8.86 over the past decade. While the company's 10-year median is 3.85 vs. the industry median of 0.58, 10x Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Cash Ratio of 4.75 is 719% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Cash Ratio is 4.75, which is 23% above median its own 10-year median of 3.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.78, compared to a current price of $55.51 — trading 195.6% above its estimated fair value. The current Cash Ratio is 4.75, which is 23% above median its 10-year median of 3.85 and 719% above the Healthcare Providers & Services industry median of 0.58. 10x Genomics' overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For 10x Genomics (TXG), the current Cash Ratio is 4.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $55.51 is trading 195.6% above its estimated GF Value™ of $18.78.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Cash Ratio: 4.75 (23% above median its 10-year median of 3.85)
GF Value™: $18.78 vs. price of $55.51 (195.6% above fair value)
Industry Position: 719% above the Healthcare Providers & Services median (#56 of 665)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
61GF Score
Get the complete analysis for TXG
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
